Generally, these data demonstrated the inhibitory effects of sEV‐mDCs on the type 2 responses partially by acting on the IL‐10/IL‐10Rα axis, further indicating the potential application of the cell‐free therapy of MSC‐sEV in the treatment of allergic rhinitis. This evidence concerns the gene IL10 and allergic rhinitis.